Tumour Markers and Bone Metastases in Breast Cancer
Author Information
Author(s): Nicolini A, Ferrari P, Sagripanti A, Carpi A
Primary Institution: Department of Internal Medicine, Oncological consulting room, Pisa, Italy
Hypothesis
Can a serum tumour marker panel help identify breast cancer patients with equivocal bone scintigraphy who have bone metastases?
Conclusion
The CEA-TPA-CA15.3 tumour marker panel is effective in identifying breast cancer patients at risk for bone metastases among those with unclear bone scans.
Supporting Evidence
- 53% of patients had equivocal bone scans.
- 47 patients developed bone metastases during the study.
- The negative predictive value of the tumour marker panel was 97%.
- The positive predictive value of the tumour marker panel was 75%.
Takeaway
Doctors can use a special blood test to help figure out if breast cancer patients with unclear bone scans have bone cancer.
Methodology
The study followed 297 breast cancer patients with equivocal bone scintigraphy and assessed a tumour marker panel alongside imaging techniques.
Limitations
The study is limited to patients followed up until 1995, and the results may not apply to current practices.
Participant Demographics
Breast cancer patients who underwent mastectomy and had equivocal bone scintigraphy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website